Objective-The chemokine receptor CXCR3 is implicated in migration of leukocytes to sites of inflammation.
A therosclerosis is a progressive multifactorial disease of the larger arteries characterized by cholesterol deposition, leukocyte influx, cell death, and fibrosis. In recent years it has become increasingly clear that next to a lipid storage disorder, atherosclerosis can be considered as an ongoing inflammatory process within the vasculature. 1, 2 Migration of leukocytes into the vessel wall is an essential step in atherosclerotic lesion formation and progression, and chemokines are defined as key regulators of this process. 3, 4 Chemokine receptors are trans-membrane spanning, G protein-coupled receptors which are classified by the position of the N-terminal cysteins (CC, CXC, C, CXXXC). They play an important role in the recruitment, migration, and trafficking of immune cells to sites of inflammation. An increasing amount of evidence underscores the relevance of chemokines in the pathogenesis of atherosclerosis. [5] [6] [7] [8] [9] [10] The chemokine receptor CXCR3 is expressed on different types of leukocytes, including T cells, B cells, natural killer (T) cells, and monocytes. [11] [12] [13] [14] Its expression is highly induced on CD4 T cell activation and is preferentially expressed on activated autoreactive T cells. 15 Antibody-mediated blockade of CXCR3 results in a decreased recruitment of Th1 cells to sites of inflammation. 16 Recent publications point toward a prominent role for CXCR3-mediated migration of inflammatory cells in atherosclerosis. Human atherosclerotic lesions express high amounts of all 3 CXCR3 ligands. 17 Targeted deletion of CXCR3 in ApoE-deficient (ApoE Ϫ/Ϫ ) mice resulted in decreased lesion formation in the abdominal aorta. 5 Furthermore, deletion of the CXCR3 ligand CXCL10 in ApoE Ϫ/Ϫ mice resulted in decreased lesion formation by reducing the migration of CD4 effector T cells to the atherosclerotic plaque. 18 Blockade of CXCR3-mediated migration could provide a potential strategy to reduce leukocyte migration to sites of inflammation and in this way attenuate atherosclerotic lesion formation. We describe that the highly specific CXCR3 antagonist NBI-74330 inhibits cell migration and dietinduced atherosclerosis in LDL receptor-deficient mice.
Materials and Methods

Determination of Appropriate In Vivo Dosage of NBI-74330
The quinazolinone-derived CXCR3 antagonist NBI-74330 was synthesized as described by Medina et al (Patent WO02083143, USA, Oct 24, 2002) . Mice were treated with NBI-74330 in 1% Na Docusate in 0.5% 400Cp Methylcellulose and serum concentration at indicated time points were determined using LC-MS-MS. Serum was subjected to protein precipitation before analysis. High-performance liquid chromatography (HPLC) mobile phase consisted of H 2 O with 0.1% (v/v) formic acid and Acetonitrile with 0.1% (v/v) formic acid using a gradient profile.
Peritonitis-Induced Migration and Mobility Assay
LDLr Ϫ/Ϫ mice were treated with a subcutaneous injection of 100 mg/kg NBI-74330 (nϭ6) or vehicle (nϭ5) for 6 days. At day 2, all mice were injected intraperitoneally with sterile 3% (wt/vol) Brewers thioglycolate solution. Peritoneal cells were isolated by peritoneal cavity lavage with PBS and counted and phenotyped by flow cytometry at day 6.
Migration capacity of the isolated peritoneal cells in response to CXCL10 (100 ng/mL), and the chemotactic peptide FMLP (1 mol/L) was quantified using a chemokinesis assay. 19 
Atherosclerosis Experiments
Female LDLr Ϫ/Ϫ mice, 10 weeks old (nϭ8 to 12 per group), were fed a Western-type diet containing 0.25% cholesterol and 15% cocoa butter 2 weeks before collar placement. 20 Mice were treated with a subcutaneous injection of 100 mg/kg NBI-74330 every day during the entire experiment. After 8 weeks of Western-type diet and treatment, the mice were euthanized and organs were harvested for histology, fluorescence-activated-cell sorter (FACS) analysis, and RNA isolation. Blood samples were collected by tail bleeding from nonfasted animals, and concentrations of serum cholesterol and triglycerides were determined using enzymatic colorimetric procedures.
Histological Analysis
Cryostat sections of the aortic root (10 m) were collected and stained with oil red O. Lesion size was determined in 5 sections of the aortic valve leaflet area. Corresponding sections on separate slides were stained immunohistochemically with an antibody directed against a macrophage specific antigen (MOMA-2, monoclonal rat IgG2b, diluted 1:50). Goat anti-rat IgG-AP (dilution 1:100) was used as secondary antibody and NBT-BCIP as enzyme substrates. Masson trichrome staining (Sigma Diagnostics) was used to visualize collagen (blue staining). Transforming growth factor (TGF)-␤ was stained with a polyclonal rabbit antibody (Santa Cruz), and biotinylated goat anti rabbit (Dako Cytomatics) was used as a secondary antibody with Nova Red as enzyme substrate (Vector Laboratories).
Real-Time Polymerase Chain Reaction Assays
Total RNA was isolated from aortic arch and collar induced atherosclerotic plaques and was DNase treated. Quantitative gene expression analysis was performed on an ABI PRISM 7500 (Applied Biosystems) using SYBR Green technology. Polymerase chain reaction primers (supplemental Table I , available online at http:// atvb.ahajournals.org) were designed using Primer Express 1.7 software with the manufacturer's default settings (Applied Biosystems). Acidic ribosomal phosphoprotein PO (36B4) and hypoxanthine phosphoribosyl transferase (HPRT) were used as housekeeping genes.
Flow Cytometry
Leukocytes from whole blood and spleen were isolated by density gradient centrifugation with Lympholyte (Cedarlane Laboratories). Cell suspensions from spleen, blood, lymph nodes draining from the aortic arch, and peritoneal cavity were stained for surface markers (0.2 g Ab/300.000 cells) and subsequently subjected to flow cytometric analysis (FACS). Antibodies were purchased from Immunoscource (Belgium). All data was acquired on a FACSCalibur and was analyzed with CELLQuest software (BD Biosciences).
Statistical Analysis
Values are expressed as meanϮSEM unless indicated otherwise. Two-tailed Student t test was used to compare normally distributed data between 2 groups of animals. Mann-Whitney test was used to compare not normally distributed data. A probability value of PϽ0.05 was considered to be significant for both tests.
Results
In Vivo Use of NBI-74330
NBI-74330 is a small molecular high affinity CXCR3 antagonist that is a potent inhibitor of CXCR3 ligand binding with a K i in the low nanomolar range (Ϸ8 nmol/L). In vitro data have shown that it inhibits CXCL10 and ITAC induced calcium mobilization at concentrations below 10 nmol/L. 21 A formulation of NBI-74330 was constructed using 1% Na Docusate in 0.5% 400Cp Methylcellulose. We tested the optimal dosing of this formulation in vivo and found that daily dosage of 100 mg/kg via subcutaneous injections resulted in serum concentrations of approximately 1 mol/L ( Figure 1 ). This concentration is sufficient to fully block the CXCR3 receptor in vivo.
The CXCR3 Antagonist NBI-74330 Inhibits CD4 ؉ T Cell and Macrophage Migration During Thioglycolate-Induced Peritonitis
To show the in vivo capacity of NBI-74330 to antagonize CXCR3-mediated cell migration, we used a peritonitis model. In this model, leukocytes migrate to the peritoneal cavity in response to a single intraperitoneal thioglycollate challenge. Female LDLr Ϫ/Ϫ mice were treated with NBI-74330 or control for 6 days. At day 2 in all mice peritonitis was induced, and 5 days later the number of cells present in the peritoneum was quantified. A significant 56% reduction in leukocyte recruitment could be observed after 5 days in NBI-74330 -treated mice compared with control-treated mice (Figure 2A ; Pϭ0.01). FACS analysis of the isolated peritoneal cells showed that this reduction was mainly attributable to reduced migration of CD4 ϩ T cells and macrophages (Figure 2A ). To investigate the capacity of the isolated peritoneal cells from control and NBI-74330 -treated mice to migrate in response to the CXCR3 ligand CXCL10 we performed an ex vivo mobility study. Isolated peritoneal cells from control and treated mice were allowed to accumulate at the lower end of a 96-well culture plate, and migration in response to 100 ng/mL CXCL10 and FMLP (positive control) was then assessed ( Figure 2B ).
Peritoneal cells isolated from mice treated with vehicle for 6 days had a clear migratory response when exposed to 100 ng/mL CXCL10, and this effect was completely reversed by the in vitro addition of NBI-74330 to the culture medium. Cells isolated from in vivo NBI-74330 -treated mice during the thioglycollate challenge were not able to respond to CXCL10. Their capability to migrate while exposed to the general chemotactic peptide FMLP was not different from control-treated mice.
These findings clearly show that the reduced migration toward thioglycollate-induced peritonitis by NBI-74330 treatment is the result of an effective in vivo blockade of CXCR3.
Atherosclerotic Lesion Formation in LDLr ؊/؊ Mice Is Attenuated by Antagonizing CXCR3
LDLr Ϫ/Ϫ mice on a Western type diet were used as a model for atherosclerosis and mRNA expression of CXCR3 during lesion formation was monitored in the aortic arch at different time points of Western-type diet feeding. A significant increase was observed in CXCR3 mRNA expression after 9 weeks of diet, indicating initial influx of CXCR3 expressing leukocytes (Figure 3 ). We then assessed the effect of NBI-74330 treatment on atherosclerotic lesion formation.
Female LDLr Ϫ/Ϫ mice were fed a Western-type diet and received daily subcutaneous injections of 100 mg/kg NBI-74330 or vehicle. No difference was observed in serum cholesterol and triglyceride levels between control and treated animals (supplemental Table II ). Figure 4 shows representative sections of control-treated ( Figure 4A ) and NBI-74330 -treated ( Figure 4B ) mice. Atherosclerotic lesion formation in the aortic valve leaflet area was significantly inhibited in mice treated with NBI-74330 (536ϫ10 3 m 2 versus 391ϫ10 3 m 2 ; PϽ0.05). Relative macrophage staining (MOMA-2) was comparable in plaques from control and treated animals, as well as the relative collagen content as determined by Masson trichrome staining (supplemental Figure II) .
We also quantified the lesion area in the aorta of control and NBI-74330 -treated mice by en face staining with oil red O. Representative pictures of control ( Figure 4D ) and NBI-74330 treated aortas ( Figure 4E ) are shown. NBI-74330 treatment resulted in a 53% reduction in lesion formation compared with control treated mice (18Ϯ2% versus 8Ϯ2%, Pϭ0.01).
CXCR3 Antagonist-Treated Mice Have Smaller Draining Lymph Nodes and a Beneficial Regulatory/Effector T Cell Balance
Recent publications suggest a role for CXCR3 in the migration of effector cells toward the site of inflammation. 18, 22, 23 We isolated the lymph nodes draining from the aortic arch of LDLr Ϫ/Ϫ mice after 8 weeks of Western-type diet and control or NBI-74330 treatment. Treatment with NBI-74330 resulted in a 64% reduction in cell numbers in lymph nodes draining from the aortic arch ( Figure 5A ). Characterization of the isolated cell population was performed using FACS.
A specific enrichment in CD25 high (3.1% in controls versus 10.1% in treated) cells within the CD4 ϩ T cell population was observed in NBI-74330 -treated mice ( Figure 5B, PϽ0.05) . The CD4 ϩ CD25 high regulatory T cells represent 0.6% of the total lymph cell population in controls (data not shown). This increase in regulatory T cells was accompanied by an increase in the expression of CD62L on CD4 cells 
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Antagonizing CXCR3 Decreases Atherosclerosis (PϽ0.001), suggesting a reduction in the activation state of effector T cells. These effects were restricted to the lymph nodes draining from the aortic arch, as were not observed in spleen or the circulating white blood cell population.
Plaques From Mice Treated With NBI-74330 Express More Genes Associated With Regulatory T Cells
To determine whether the local reduction in effector cells and the increase in regulatory T cell phenotype resulted in a resembling cytokine profile inside the atherosclerotic plaque we stained for the regulatory T cell cytokine TGF-␤. Representative slides are shown for control ( Figure 6A ) and NBI-74330 -treated ( Figure 6B ) mice. A significant increase was observed in the relative expression of TGF-␤ in the plaque of mice treated with NBI-74330 compared with control ( Figure 6C ). We performed QPCR on atherosclerotic plaques isolated from the carotid artery after collar-induced atherosclerosis from both control and treated mice and determined the expression of the regulatory T cell-associated genes Foxp3, CD25, and CTLA-4 ( Figure 6D ). The expression of Foxp3 was 2.5 fold upregulated (PϽ0.05), and the expression of CTLA-4 was 6-fold upregulated (PϽ0.05) compared with expression in control-treated mice. The expression of CD25 showed a trend toward an increased expression, but this was not significant.
Discussion
Evidence is building that CXCR3-mediated cell migration plays an important role in several (auto)immune diseases. 24 -27 CXCR3 positive cells enter the site of inflammation followed by a local upregulation of CXCR3 expression. These CXCR3-positive cells are attracted by the 3 known ligands, CXCL9, -10, and -11, and it was shown that these ligands are highly expressed in atherosclerotic lesions. 17 In this study we used the highly specific CXCR3 antagonist NBI-74330 to block CXCR3-mediated signaling and migration. Firstly, we showed the in vivo capacity of this compound to reduce cell migration to a site of inflammation using a thioglycollate-induced peritonitis model. Total leukocyte migration to the peritoneal cavity was reduced by 56% on daily treatment with NBI-74330. The reduction in total cell migration was the consequence of a reduction in the number of CD4 ϩ T cells and macrophages to the peritoneal cavity. The observed decrease in migration was the result of selective blockage of CXCR3, as shown by a subsequent ex vivo mobility assay. Peritoneal cells isolated from control mice were able to migrate in response to both CXCL10 and FMLP. Cells isolated from mice that received NBI-74330 during the induction of peritonitis were not responsive to CXCL10 but were still capable of migrating in response to an FMLP stimulus.
After we established the in vivo efficacy of the compound, we used LDL receptor-deficient mice to test the effect of antagonizing CXCR3 on atherosclerotic lesion formation.
We show that the expression of CXCR3 is upregulated in the aortic arch of LDLr Ϫ/Ϫ mice fed a Western type diet for 9 weeks. This indicates that CXCR3-positive leukocytes migrate to the developing atherosclerotic plaque. It was shown that CXCR3-deficient mice on an ApoE background show reduced lesion burden compared with control ApoE mice. In addition, mice lacking CXCL10, the main ligand for CXCR3, show decreased atherogenesis compared with control ApoE mice. These are interesting observations, clearly suggesting that CXCR3 is involved in the disease initiation and progression of atherosclerosis in ApoE-deficient mice. However, these mice lack the expression of these proteins throughout their development and compensating mechanisms to overcome this deficiency may have taken place.
In this study, we use the compound NBI-74330, a highly specific low molecular weight CXCR3 antagonist, to investigate the effect of antagonizing CXCR3 in a diet-induced model for atherosclerosis. Treatment with NBI-74330 resulted in a significant decrease in atherosclerotic lesion formation at the aortic valve leaflet area as well as the total aorta. We observed a more pronounced decrease in lesion size in the aorta compared with the valve leaflet area. In their study with CXCR3/ApoE-double deficient animals, Veillard et al also showed a difference in lesion formation between these 2 sites, because they observed a significant decrease in the degree of lesion formation in the descending aorta was observed but no effect in the aortic sinus. They suggest a more prominent role for CXCR3 in the initial stages of lesion formation. Our findings strengthen this idea as we had quite large and advanced lesions in the valves, whereas the lesion burden in the aorta was more moderate.
As shown, CXCR3 mediates the migration of effector cells to the site of inflammation. Absence of CXCR3 or its main ligand CXCL10 in mice on an ApoE background resulted in an induction of regulatory T cells markers within the atherosclerotic plaque but not in lymph nodes or circulation.
Our experiments clearly show that administration of a pharmacologically active CXCR3 antagonist results in smaller lymph nodes draining from the aortic arch compared with control-treated mice. The activation state of T cells is decreased and regulatory phenotype is enhanced in these lymph nodes of NBI-74330 -treated mice.
When LDLr Ϫ/Ϫ mice are fed a Western-type diet, the lymph nodes draining from the aortic arch increase in size because of local inflammatory signals. Administering a CXCR3 antagonist clearly reduced the migration of leukocytes to the lymphatic sites draining to the site of inflammation. This indicates not only that direct migration of effector cells from the circulation to the atherosclerotic plaque is inhibited, but also that migration to the draining lymph system is beneficially modulated. Possibly CXCL9 and -11 are involved in this process, because no increase in regulatory T cells was observed in lymph cells isolated from CXCL10-deficient mice.
Furthermore we observe that NBI-74330 -treated mice have an increased number of CD4 ϩ CD25 high regulatory T cells in the lymph nodes draining directly from the aortic arch 28 and an increased expression of the regulatory T cell markers Foxp3, CTLA-4, and CD25 within the atherosclerotic plaque and increased TGF-␤ levels. This indicates that regulatory T cells are the likely source of the observed increase in (surface bound) TGF-␤ expression within the atherosclerotic plaque 29 -34 and inhibit the local effector T cell responses.
We hypothesize that the observed reduction in lesion formation and the accompanying induction of a regulatory T cell phenotype results from a reduction in migration of effector cells to the atherosclerotic plaque and to the draining lymph nodes, which leads to a relative induction of antiinflammatory and regulatory cells. Eventually, because of the continuing exposure to antigens such as oxLDL or heat shock proteins, the ongoing attraction of leukocytes via other pathways than CXCR3 will facilitate the process of lesion formation. The blockade of CXCR3 thus provides a "lagtime" in this response.
It is clear that selective blockade of CXCR3 migration in vivo using NBI-74330 provides an attractive way to beneficially balance the immune response in an autoinflammatory situation such as atherosclerosis. A possible drawback of interfering with CXCR3-mediated migration could be a potentially hampered immune response against invading pathogens. For example, lung infection with B Bronchiseptica results in strong upregulation of CXCR3 ligands and influx of CXCR3 ϩ cells. However, CXCR3-deficient mice do not show increased mortality to this pathogen. Furthermore, Chackavarty et al have showed that CXCR3-deficient mice are more resistant to Mycobacterium tuberculosis infection. 35 CXCR3 is also associated with cellular influx into CMVinfected liver. Infection of the liver with CMV attracts CXCR3 ϩ CD8 ϩ cells that contribute to the protective response to the virus, but these cells are not exclusively required for its clearance. 36 Based on these observations treatment with a selective CXCR3 antagonist is unlikely to result in severe infections with pathogens.
Small molecular antagonists are the preferential and most widely used drugs and have clear advantages over protein or antibody formulations. We conclude that this study shows for the first time that a small molecular CXCR3 antagonist inhibits lesion formation in an animal model for atherosclerosis. This study therefore provides evidence that CXCR3 antagonists can be a possible new therapeutic strategy to counteract the development of atherosclerosis or other (auto) immune diseases.
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